Antiviral agents

Abstract

Provided is an antiviral agent that is not only suitable for use in an article but also suitable for use in a living organism and is safer for the living organism. The antiviral agent contains a mannosylerythritol lipid (MEL) as an effective ingredient, preferably contains 0.000001 to 100% by weight, and is applicable to a living organism or an article.

Description

Technical Field

[0001] This invention relates to antiviral agents. More specifically, it relates to antiviral agents that are suitable not only for use in articles but also for use in organisms, and that offer greater safety to organisms. Background Technology

[0002] Viruses are classified as non-cellular organisms, distinct from living organisms, and multiply by infecting host cells of mammals, birds, and other similar species. Viruses cause infectious diseases such as foot-and-mouth disease and avian influenza, gradually becoming a social problem. Furthermore, recent improvements in living environments and changes in hygiene awareness have created a demand for substances with excellent antiviral and virus-inactivating effects, capable of killing viruses present in the environment.

[0003] To prevent viral infections, various methods for killing viruses in the environment have been studied. Examples include physical treatments such as heat treatment and ultraviolet light treatment, as well as chemical treatments such as chlorine bleach and peroxides. These treatments can damage organisms and objects, making them unsafe for use in various situations. Therefore, there is an urgent need for antiviral agents or virus inactivators that are suitable not only for objects but also for organisms, and with higher safety for organisms, especially during pandemics.

[0004] On the other hand, mannose erythritol ester (MEL) is a natural surfactant produced by yeast, and various physiological effects (Non-Patent Literature 1) and antibacterial effects (Patent Literature 1) have been reported. Furthermore, regarding its use as a topical agent and in cosmetics, it has been reported to improve rough skin (Patent Literature 2). Therefore, it can be said that MEL is a material with various physiological activities and high safety for organisms. However, the antiviral or virus-inactivating effects of MEL have not yet been confirmed.

[0005] Existing technical documents

[0006] Patent documents

[0007] Patent Document 1: Japanese Patent Application Publication No. 57-145896

[0008] Patent Document 2: WO2007 / 060956

[0009] Non-patent literature

[0010] Non-patent literature 1: Journal of Biosciense and Bioengineering, 94, 187 (2002).

[0011] Non-patent literature 2: Biologicals, 25, 3, pp. 289-297 (1997) Summary of the Invention

[0012] The problem the invention aims to solve

[0013] The objective of this invention is to provide an antiviral agent that is suitable not only for use in articles but also for use in organisms and is safer for organisms.

[0014] Solution for solving the problem

[0015] The inventors discovered that MEL, as a biosurfactant, has excellent antiviral effects, thus completing this invention.

[0016] Specifically, the present invention can be illustrated by the following embodiments.

[0017] Item 1. An antiviral agent containing mannose erythritol ester (MEL) as an active ingredient.

[0018] Item 2. The antiviral agent according to Item 1, wherein the content of mannose erythritol ester (MEL) is 0.000001 to 100 by weight.

[0019] Item 3. The antiviral agent according to Item 2, wherein the content of mannose erythritol ester (MEL) is 0.000001 to 80% by weight.

[0020] Item 4. The antiviral agent according to Item 2, wherein the content of mannose erythritol ester (MEL) is 0.0001 to 10 by weight.

[0021] Item 5. The antiviral agent according to any one of items 1 to 4, wherein the mannose erythritol ester (MEL) is any one selected from the group consisting of MEL-A, MEL-B, MEL-C and MEL-D.

[0022] Item 6. An antiviral agent according to any one of items 1 to 5, wherein the mannose erythritol ester (MEL) has the structure of formula (2).

[0023]

[0024] (In the formula, R1 is an aliphatic acyl group with 4 to 24 carbon atoms, which may be the same or different. R2 is a hydrogen or acetyl group, which may be the same or different. R3 is a hydrogen or an aliphatic acyl group with 2 to 24 carbon atoms.)

[0025] Item 7. An antiviral agent according to any one of items 1 to 5, wherein the mannose erythritol ester (MEL) has the structure of formula (3).

[0026]

[0027] (In the formula, R1 is an aliphatic acyl group with 4 to 24 carbon atoms, which may be the same or different. R2 is a hydrogen or acetyl group, which may be the same or different. R3 is a hydrogen or an aliphatic acyl group with 2 to 24 carbon atoms.)

[0028] Item 8. The antiviral agent according to any one of items 1 to 5, wherein the mannose erythritol ester (MEL) is MEL-B.

[0029] Item 9. The antiviral agent according to Item 8, wherein MEL-B has the structure of formula (4).

[0030]

[0031] (In the formula, R1 is a saturated or unsaturated straight-chain or branched aliphatic acyl group with 2 to 20 carbon atoms, which may be the same or different.)

[0032] Item 10. The antiviral agent according to Item 8, wherein MEL-B has the structure of formula (5).

[0033]

[0034] (In the formula, R1 is a saturated or unsaturated straight-chain or branched aliphatic acyl group with 2 to 20 carbon atoms, which may be the same or different.)

[0035] Item 11. The antiviral agent according to any one of items 1 to 10, wherein the virus targeted is an enveloped virus.

[0036] Item 12. The antiviral agent according to Item 11, wherein the virus to be targeted is an influenza virus.

[0037] Item 13. The antiviral agent according to Item 11, wherein the virus being targeted is a human coronavirus.

[0038] Item 14. The antiviral agent according to any one of items 1 to 13, which is used for application to an organism.

[0039] Item 15. The antiviral agent according to any one of items 1 to 13, which is used to apply to articles.

[0040] Item 16. A cosmetic product containing any one of items 1 to 14.

[0041] Item 17. A disinfectant comprising any one of items 1 to 15 of the antiviral agent.

[0042] Item 18. A cleaning agent comprising any one of items 1 to 15 of the antiviral agent.

[0043] The effects of the invention

[0044] By utilizing the MEL-containing compositions of the present invention, antiviral agents that are suitable not only for articles but also for organisms and are safer for organisms can be provided. Attached Figure Description

[0045] Figure 1 A graph showing the results of testing the virus inactivation effect on human coronaviruses in Example 1.

[0046] Figure 2 A graph showing the results of testing the virus inactivation effect on influenza virus in Example 1. Detailed Implementation

[0047] In this invention, antiviral agents refer to drugs that are effective in treating and preventing viral infections by inhibiting viral proliferation or by rendering viruses attached to organisms or objects infectious. It is generally believed that destroying the external tissues of a virus can cause it to lose its ability to invade biological cells and proliferate, thus terminating its activity.

[0048] Biosurfactants are a general term for substances produced by organisms that possess surface-active and emulsifying abilities. They not only exhibit excellent surface activity and high biodegradability but also possess various physiological functions, thus potentially displaying behaviors and functions different from synthetic surfactants. Currently, biosurfactants can be classified into five types: glycolipids, acyl peptides, phospholipids, fatty acids, and polymers. Glycolipid-type biosurfactants contain both carbohydrate and fatty acid components; a preferred example is mannoerythritol ester (MEL).

[0049] The type of MEL used in this invention is not particularly limited, and examples include MEL-A, MEL-B, MEL-C, and MEL-D. Among them, MEL-B is particularly preferred.

[0050] The structure of MEL is shown in general formula (1). In general formula (1), the substituent R1 can be the same or different and is an aliphatic acyl group with 4 to 24 carbons. MEL can be divided into four types, MEL-A, MEL-B, MEL-C and MEL-D, based on the presence or absence of acetyl groups at the 4 and 6 positions of mannose.

[0051]

[0052] Specifically, in MEL-A, substituents R2 and R3 in general formula (1) are both acetyl groups. In MEL-B, substituent R2 in general formula (1) is hydrogen and substituent R3 is acetyl. In MEL-C, substituent R2 in general formula (1) is acetyl and substituent R3 is hydrogen. In MEL-D, substituents R2 and R3 in general formula (1) are both hydrogen.

[0053] The number of carbons in substituent R1 in MEL-A to MEL-D varies depending on the number of carbons in the fatty acids constituting the triglycerides in the MEL production medium and the degree of fatty acid assimilation by the MEL-producing bacteria used. Furthermore, if the triglycerides contain unsaturated fatty acid residues, substituent R1 may also contain unsaturated fatty acid residues if the MEL-producing bacteria do not assimilate the double bond portion of the unsaturated fatty acids. As described above, the resulting MEL is typically a mixture of compounds with varying fatty acid residue motifs in substituent R1.

[0054] As a preferred example of the antiviral agent of the present invention, it contains MEL having the structure shown in general formula (2) or general formula (3). In general formulas (2) and (3), the substituent R1 may be the same or different. It is an aliphatic acyl group having 4 to 24 carbons, preferably 8 to 14. The substituent R2 may be the same or different, and is hydrogen or acetyl. The substituent R3 is hydrogen or an aliphatic acyl group having 2 to 24 carbons.

[0055] Furthermore, the substituent R1 in the above general formulas (2) and (3) can be either a saturated aliphatic acyl group or an unsaturated aliphatic acyl group, without particular limitation. In the case of unsaturated bonds, for example, multiple double bonds can be present. The carbon chain can be straight or branched. In addition, in the case of hydrocarbon groups containing oxygen atoms, the number and position of the oxygen atoms are not particularly limited.

[0056]

[0057]

[0058] The fatty acid in the erythritol portion of the MEL can be any monocarboxylic acid of a long-chain hydrocarbon. It can be either a saturated or unsaturated fatty acid. When unsaturated, it can have multiple double bonds. The carbon chain can be straight or branched. Furthermore, fatty acid derivatives, which are derivatives of fatty acids, can be used in this invention, as can mixtures of fatty acids and fatty acid derivatives. The fatty acid or fatty acid derivative in the erythritol portion of the MEL is preferably derived from oils, higher fatty acids, or synthetic esters.

[0059] The MEL used in this invention is preferably MEL-B having the structure shown in general formula (4) or general formula (5). More preferably, it is MEL-B having the structure shown in general formula (4).

[0060]

[0061]

[0062] In general formulas (4) and (5), the substituent R1 can be the same or different, and can be an aliphatic acyl group with 4 to 24 carbon atoms.

[0063] It should be noted that in this invention, one type of MEL can be used alone, or two or more types of MEL can be used in combination.

[0064] There are no particular limitations on the viruses that can be used as the antiviral agent of this invention; it can be applied to either enveloped viruses (viruses with an envelope) or non-enveloped viruses (viruses without an envelope). Examples of enveloped viruses include, for example, influenza viruses (e.g., influenza A, B, etc.), rubella virus, Ebola virus, coronavirus, measles virus, varicella-zoster virus, herpes simplex virus, mumps virus, arbovirus, RS virus, SARS virus, hepatitis viruses (e.g., hepatitis B virus, hepatitis C virus, etc.), yellow fever virus, HIV, rabies virus, Hantavirus, dengue virus, Nipah virus, Lyssa virus, etc. Examples of non-enveloped viruses include, for example, adenovirus, norovirus, rotavirus, human papillomavirus, poliovirus, enterovirus, Coxsackievirus, human paramyxovirus, encephalocarditis virus, poliovirus, rhinovirus, etc. Enveloped viruses are preferred, with influenza viruses (such as type A and type B) and coronaviruses being particularly preferred.

[0065] The antiviral agent of this invention can be widely used in various fields requiring antiviral properties. For example, it can be used in various fields such as industry, cleaning, medicine, food, and daily necessities. The antiviral agent of this invention is applicable to any use, both for biological purposes and for article purposes.

[0066] In this invention, the organism can include tissues, cells, etc., derived from living organisms. Examples of uses when applied to living organisms include cosmetics, disinfectants, and cleaning agents. The target organism is not particularly limited, but preferably includes various mammals such as humans, monkeys, mice, rats, dogs, cats, rabbits, pigs, horses, cattle, sheep, goats, and deer.

[0067] By applying the antiviral agent of the present invention to organisms, antiviral effects and / or virus inactivation effects can be exerted particularly effectively at the sites of contact with the active ingredient.

[0068] The form of the antiviral agent of the present invention is not particularly limited, and it can take the form commonly used for each application according to the purpose of the antiviral agent of the present invention.

[0069] As a form, when used in cosmetics, examples include liquids, gels, creams, ointments, and sticks.

[0070] As a form, when used as a disinfectant or cleaning agent, it can take any form, such as liquid (solution, emulsion, suspension, etc.), semi-solid (gel, cream, paste, etc.), or solid (tablet, granule, capsule, film, compound, molten solid, waxy solid, elastic solid, etc.). For example, if used in the oral cavity, more specifically, examples include toothpaste (toothpaste, liquid toothpaste, liquid toothpaste, tooth powder, etc.), mouthwash, ointments, patches, breath fresheners, and food products (e.g., chewing gum, candy, candy, gummies, films, chewable tablets, etc.). If used in the nasal cavity, more specifically, examples include nasal sprays. If used on the skin, examples include soap, shower gel, shampoo, conditioner, and sprays.

[0071] The antiviral agent of the present invention may further include other ingredients as needed. These other ingredients are not particularly limited as long as they are compatible with, for example, cosmetics, disinfectants, and cleaning agents, and examples include: oil-based substrates, water-based substrates, powder-based substrates, and polymer-based substrates; carriers such as alumina and silica; solvents such as water and alcohol; dispersants such as sodium polyacrylate; emulsifiers such as glycerol fatty acid esters and lecithin; buffers such as citrate; stabilizers such as sodium sulfite; excipients such as mannitol; binders such as microcrystalline cellulose; disintegrants such as calcium carboxymethyl cellulose; lubricants such as magnesium stearate and talc; thickeners such as gum arabic and xanthan gum; humectants such as glycerin; chelating agents such as EDTA; colorants; and fragrances.

[0072] The MEL content of the antiviral agent of the present invention is affected by the type of active ingredient, its use, method of use, target of application, and state of the target of application, and is not limited thereto. It can be set to, for example, 0.000001 to 100% by weight, preferably 0.000001 to 80% by weight, more preferably 0.00001 to 80% by weight, even more preferably 0.0001 to 50% by weight, and particularly preferably 0.0001 to 10% by weight.

[0073] When used on items, examples include disinfectants and cleaning agents. There are no particular restrictions on the objects of application; examples include industrial products and their raw materials used in various fields.

[0074] In this invention, "articles" refers to all objects used in daily life, excluding living organisms. Specifically, examples include: office automation equipment, household appliances, air conditioning equipment, vacuum cleaners, tables, chairs, sofas, benches, windows, armrests, steering wheels, seats, automatic ticket gates, automatic ticket vending machines, vending machines, doors, fences, railings, tableware, cooking utensils, packaging films, packaging bags, jars, bottles, packaging materials, sinks, toilets, stationery, books, bookshelves, toothbrushes, mirrors, air conditioner filters, masks, coats, and clips. Clothing, including but not limited to: coats, trousers, skirts, dress shirts, knitwear, tops, sweaters, wool sweaters, pajamas, base layers, underwear, diapers, protective gear, socks, tights, pantyhose, hats, scarves, neck warmers, shawls, gloves, linings for clothing, padding for clothing, inner linings for clothing, work clothes, uniforms, school uniforms, curtains, screen doors, bedding fabrics, bedding fillings, bedding covers, pillowcases, sheets, mats, carpets, towels, handkerchiefs, wallpaper, adhesive tape, bandages, etc.

[0075] By applying the antiviral agent of the present invention to articles, it can exert antiviral effects and / or virus inactivation effects, particularly at the sites in contact with the active ingredient.

[0076] The dosage form of the antiviral agent of the present invention is not particularly limited and can be appropriately selected according to its use. Examples of dosage forms include liquids, emulsions, suspensions, dispersants, aerosols, etc., as well as solids or semi-solids such as powders, granules, microparticles, and flowable agents.

[0077] The antiviral agent of the present invention may further include other ingredients as needed. These other ingredients are not particularly limited to those that can be used in, for example, cleaning agents, disinfectants, etc., and examples include: oil-based substrates, water-based substrates, powder-based substrates, polymer-based substrates; carriers such as alumina and silica; solvents such as water and alcohol; dispersants such as sodium polyacrylate; emulsifiers such as glycerol fatty acid esters and lecithin; buffers such as citrate; stabilizers such as sodium sulfite; excipients such as mannitol; binders such as microcrystalline cellulose; disintegrants such as calcium carboxymethyl cellulose; lubricants such as magnesium stearate and talc; thickeners such as gum arabic and xanthan gum; humectants such as glycerin; chelating agents such as EDTA; colorants; fragrances, etc.

[0078] The present invention will be described in more detail below based on embodiments. It should be noted that the present invention is not particularly limited by the embodiments.

[0079] Example

[0080] Example 1

[0081] The virus inactivation effect was evaluated using the substance obtained by suspending MEL in purified water as the test sample through the following test method.

[0082] As the sample solution for the human coronavirus inactivation test, the substance obtained by suspending MEL-B in purified water at a concentration of 0.005% (w / v) or 0.01% (w / v) is used as the test sample.

[0083] As the sample solution for the influenza virus inactivation test, the substance obtained by suspending MEL-B in purified water at a concentration of 0.01% (w / v) or 0.1% (w / v) was used as the test sample.

[0084] As experimental viruses, Human coronavirus 229E ATCC VR-740 (human coronavirus) and Influenza A virus A / PR / 8 / 34 ATCC VR-1469 (influenza virus) were used.

[0085] Human coronaviruses were cultured using MRC-5 cells ATCC CCL-171. As the maintenance medium, Igor MEM medium "Nissui" (1) (manufactured by Nissui Pharmaceutical Co., Ltd.) with 2% fetal bovine serum added and adjusted to approximately pH 8.0 was used.

[0086] Influenza virus was cultured using MDCK (NBL-2) cells, strain JCRB9029. The maintenance medium was prepared by adjusting the following components to approximately pH 8.0.

[0087] • Igor MEM medium “Nissui” (1) 1000mL

[0088] 14 mL of 10% NaHCO3

[0089] L-Glutamine (30g / L) 9.8mL

[0090] • Use 30mL of vitamin solution for 100×MEM

[0091] 10% albumin 20mL

[0092] · 0.25% trypsin 20mL

[0093] The virus culture medium was centrifuged, and 0.1 mL of the supernatant was added to 1 mL of the sample solution. The mixture was allowed to react at room temperature for 1 minute or 15 minutes. As a control, 0.1 mL of purified water was allowed to react with the sample solution for 0 minutes or 15 minutes.

[0094] The above-described reaction solution was inoculated into cultured cells and cultured in maintenance medium at 5% CO2 for 7 days. After culture, morphological changes (cytopathic effect) were observed in the cells, and the concentration of the sample solution at which 50% of the cultured cells were infected with the virus was calculated. The virus inactivation effect per 1 ml (TCID50 / ml) was then determined. The results are presented below. Figure 1 and 2 .

[0095] At 0.005% MEL, the viral infection titer of human coronavirus decreased by approximately one order of magnitude. Furthermore, at 0.01% MEL, the viral infection titer decreased by more than two orders of magnitude. Based on these results, MEL exhibits antiviral or viral inactivation effects against human coronaviruses even at extremely low concentrations.

[0096] Under conditions of 0.01% and 0.1% MEL, the influenza virus infection titer decreased by about an order of magnitude. It can be considered that the antiviral effect or virus inactivation effect of this invention is the result of the physicochemical interaction between the surface activity of MEL and the viral lipid membrane.

[0097] Example 2

[0098] The following are examples of formulations for the disinfectant used in this invention.

[0099] MEL-B 0.1% (w / v)

[0100] • Bis-PEG / PPG-[14-20] / [5-20]-polydimethylsiloxane 1% (w / v) • Ethanol 80% (w / w)

[0101] • Purified water present in an amount of 100% by mass of the entire composition

[0102] Example 3

[0103] The following are examples of formulations for the disinfectant used in this invention.

[0104] MEL-B 0.1% (w / v)

[0105] • Ethanol 35% (w / v)

[0106] • Purified water present in an amount of 100% by mass of the entire composition

[0107] Example 4

[0108] The following is a formulation example (w / v%) of the lotion in this invention.

[0109] • 0.03% hydrogenated castor oil with polyoxyethylene (60EO)

[0110] ·Polyethylene glycol 4000 1%

[0111] · Ethanol 8%

[0112] ·1,3-Butanediol 7%

[0113] 5% glycerin

[0114] ·Carboxyvinyl polymer 0.02%

[0115] • Acrylic acid / alkyl methacrylate copolymer 0.16%

[0116] Olive oil 0.4%

[0117] ·Methyl polysiloxane 0.4%

[0118] Potassium hydroxide 0.065%

[0119] ·Fragrance 0.1%

[0120] Dipotassium glycyrrhizate 0.1%

[0121] Sodium carboxymethyl-β-glucan 0.1%

[0122] MEL-B 0.01%

[0123] • Purified water present in an amount of 100% by mass of the entire composition

[0124] Example 5

[0125] The following are examples of emulsion formulations (w / v%) in this invention.

[0126] Stearic acid 0.24%

[0127] • Sorbitol monostearate 0.5%

[0128] Cetyl alcohol 0.5%

[0129] ·POE (45)-stearate 0.7%

[0130] • Cetyl palmitate 0.25%

[0131] Vaseline 3.75%

[0132] · Liquid paraffin 0.9%

[0133] · Solid paraffin 1.6%

[0134] ·PEG4000 2.25%

[0135] ·1,3-Butanediol 3%

[0136] Methylparaben 0.3%

[0137] · Glycerin 3%

[0138] Xanthan gum 0.03%

[0139] Alkyl-modified carboxyvinyl polymer 0.15%

[0140] Triethanolamine 0.15%

[0141] MEL-B 0.1%

[0142] · Sucrose lauryl ester 0.05%

[0143] 1,3-Butanediol 10%

[0144] • Purified water present in an amount of 100% by mass of the entire composition

[0145] Example 6

[0146] The following are examples of formulations (by weight %) of the cleaning agent for articles according to the present invention.

[0147] · Sodium hydroxide 3%

[0148] Sodium methacrylate 5%

[0149] 4% propylene glycol monomethyl ether

[0150] • Sodium gluconate 0.5% • Tetrasodium ethylenediaminetetraacetate 0.5%

[0151] Sodium decanoate 0.7%

[0152] ·2% Sodium 2-ethylhexanoate

[0153] MEL-B 1%

[0154] • Tocopheryl acetate 0.01%

[0155] Sodium sulfite 2%

[0156] Xanthan gum 0.3%

[0157] Example 7

[0158] The following are examples of formulations (w / v%) of the animal cleaning agent of the present invention.

[0159] Sodium benzoate 0.4%

[0160] • Sodium edetate-2- 0.05%

[0161] ·1,3-Butanediol 2%

[0162] 0.5% Chlorinated 2-hydroxy-3-(trimethylamino)propyl polyoxyethylene cellulose ether

[0163] · 30% cocamidopropyl betaine solution

[0164] • Sodium cocoyl alanine solution 30%

[0165] ·Coconut oil fatty acid monoethanolamide 2.5%

[0166] · Glycerin 2.5%

[0167] Phenoxyethanol 0.25%

[0168] MEL-B 2.0%

[0169] • 3% silicone emulsion (polydimethylsiloxane)

[0170] • Purified water present in an amount of 100% by mass of the entire composition

[0171] Industrial availability

[0172] According to the present invention, by utilizing a composition containing MEL, it is possible to provide an antiviral agent that is suitable not only for use on articles but also for use on organisms, and with higher safety for organisms. Preventive effects against viral infections can be expected in various industrial sectors such as industry, cleaning, medical, food, and daily necessities.

Claims

1. Application of mannose erythritol ester (MEL) in the preparation of antiviral agents. The mannosylerythritol lipid is any one selected from the group consisting of MEL-A, MEL-B, MEL-C, and MEL-D, wherein, The mannose erythritol ester (MEL) has the structure of formula (2) or formula (3), and the content of mannose erythritol ester (MEL) in the antiviral agent is 0.005 to 0.1% by weight. In the formula, R1 is an aliphatic acyl group with 4 to 24 carbon atoms, which may be the same or different; R2 is a hydrogen or acetyl group, which may be the same or different; R3 is a hydrogen or an aliphatic acyl group with 2 to 24 carbon atoms. The viruses selected as targets are those consisting of influenza virus, rubella virus, Ebola virus, coronavirus, measles virus, varicella-zoster virus, herpes simplex virus, mumps virus, arbovirus, RS virus, SARS virus, hepatitis virus, yellow fever virus, HIV, rabies virus, Hantavirus, dengue virus, Nipah virus, Lyssa virus, and human paramyxovirus.

2. The use according to claim 1, wherein, The mannose erythritol ester MEL is MEL-B.

3. Use according to claim 2, wherein, MEL-B has the structure of formula (4), In the formula, R1 is a saturated or unsaturated straight-chain or branched aliphatic acyl group with 2 to 20 carbon atoms, which may be the same or different.

4. The use according to claim 2, wherein, MEL-B has the structure of formula (5), In the formula, R1 is a saturated or unsaturated straight-chain or branched aliphatic acyl group with 2 to 20 carbon atoms, which may be the same or different.

5. The use according to claim 1, wherein, The virus that became the target was an enveloped virus.

6. Use according to claim 5, wherein, The virus that became the target was the influenza virus.

7. The use according to claim 5, wherein, The virus that became the target is the human coronavirus.

8. The use according to claim 1, wherein, The antiviral agent is used for application to organisms.

9. The application according to claim 1, wherein, The antiviral agent is used for application to items.

10. The use of an antiviral agent in the preparation of cosmetics, wherein the antiviral agent is any one of claims 1 to 8.

11. The use of an antiviral agent in the preparation of a disinfectant, wherein the antiviral agent is any one of claims 1 to 9.

12. The use of an antiviral agent in the preparation of a cleaning agent, wherein the antiviral agent is any one of claims 1 to 9.

Images